J&J Boosts Drug Roster With $30B Actelion Deal
The largest acquisition in J&J's history gives it access to Actelion's portfolio of high-margin treatments for rare diseases.
J&J Sales Increase 1.7% But Miss Estimates
Earnings jumped 19% to $3.81 billion in the fourth quarter, but sales were hit by slowing demand for medical devices.
Lonza to Buy Drug Capsule Maker for $5.5B
The acquisition of Capsugel will enable Lonza to offer an integrated menu of drug delivery products.
Allergan Bets on Tobira’s Liver Disease Drug
The Botox maker will pay up to $1.7 billion for Tobira, the developer of an experimental treatment for a nonalcoholic fatty liver condition.
Pfizer Makes Cancer Play With Medivation Deal
The $14 billion acquisition would add the best-selling prostate cancer drug Xtandi to Pfizer's growing oncology portfolio.